Elizabeth M Viglianti1, Paul Zajic2, Theodore J Iwashyna3, Karin Amrein2. 1. Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, USA. eviglian@med.umich.edu. 2. Department of Anesthesiology and Intensive Care Medicine, Division of General Anesthesiology, Emergency and Intensive Care Medicine, Medical University of Graz, Graz, Austria. 3. Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Michigan, Ann Arbor, MI, USA.
Abstract
OBJECTIVE: The purpose of this study was to evaluate if vitamin D deficiency is associated with increased rates of persistent critical illness, and whether repletion of vitamin D among patients with this deficiency leads to decreased persistent critical illness. DESIGN: Retrospective cohort analysis. SETTING: Seven intensive care units (ICUs) at the University Medical Center of Graz, Austria, with participants recruited between July 2008 and April 2010. The VITdAL-ICU trial cohort included five ICUs at the University Medical Center of Graz, Austria, with patients recruited between May 2010 through September 2012. PARTICIPANTS: There were 628 patients aged ≥ 18 years admitted to the ICU and who had their 25-hydroxyvitamin D (25(OH)D) level measured at least once. The VITdAL-ICU cohort included 475 patients aged ≥ 18 years who were expected to stay in the ICU for greater than 48 hours and found to have a 25(OH)D level of ≤ 20 ng/mL. MAIN OUTCOME MEASURES: Development of persistent critical illness. RESULTS: In the retrospective cohort, vitamin D level on admission was not significantly associated with the development of persistent critical illness compared with patients who were discharged alive earlier (relative risk ratio [RRR], 1.02; 95% CI, 1.00-1.04) or who died (RRR, 1.02; 95% CI, 0.99-1.05). In the VITdAL-ICU trial, supplementation with vitamin D3 did not lead to less persistent illness relative to patients who were discharged alive earlier (RRR, 1.19; 95% CI, 0.79-1.80) or who died (RRR, 1.34; 95% CI, 0.72-2.52). CONCLUSION: Vitamin D deficiency was not associated with persistent critical illness, nor did supplementation with vitamin D3 mitigate the development of persistent critical illness.
OBJECTIVE: The purpose of this study was to evaluate if vitamin D deficiency is associated with increased rates of persistent critical illness, and whether repletion of vitamin D among patients with this deficiency leads to decreased persistent critical illness. DESIGN: Retrospective cohort analysis. SETTING: Seven intensive care units (ICUs) at the University Medical Center of Graz, Austria, with participants recruited between July 2008 and April 2010. The VITdAL-ICU trial cohort included five ICUs at the University Medical Center of Graz, Austria, with patients recruited between May 2010 through September 2012. PARTICIPANTS: There were 628 patients aged ≥ 18 years admitted to the ICU and who had their 25-hydroxyvitamin D (25(OH)D) level measured at least once. The VITdAL-ICU cohort included 475 patients aged ≥ 18 years who were expected to stay in the ICU for greater than 48 hours and found to have a 25(OH)D level of ≤ 20 ng/mL. MAIN OUTCOME MEASURES: Development of persistent critical illness. RESULTS: In the retrospective cohort, vitamin D level on admission was not significantly associated with the development of persistent critical illness compared with patients who were discharged alive earlier (relative risk ratio [RRR], 1.02; 95% CI, 1.00-1.04) or who died (RRR, 1.02; 95% CI, 0.99-1.05). In the VITdAL-ICU trial, supplementation with vitamin D3 did not lead to less persistent illness relative to patients who were discharged alive earlier (RRR, 1.19; 95% CI, 0.79-1.80) or who died (RRR, 1.34; 95% CI, 0.72-2.52). CONCLUSION:Vitamin D deficiency was not associated with persistent critical illness, nor did supplementation with vitamin D3 mitigate the development of persistent critical illness.
Authors: Karin Amrein; Christian Schnedl; Alexander Holl; Regina Riedl; Kenneth B Christopher; Christoph Pachler; Tadeja Urbanic Purkart; Andreas Waltensdorfer; Andreas Münch; Helga Warnkross; Tatjana Stojakovic; Egbert Bisping; Wolfgang Toller; Karl-Heinz Smolle; Andrea Berghold; Thomas R Pieber; Harald Dobnig Journal: JAMA Date: 2014-10-15 Impact factor: 56.272
Authors: Rachel C A Dancer; Dhruv Parekh; Sian Lax; Vijay D'Souza; Shengxing Zheng; Chris R Bassford; Daniel Park; D G Bartis; Rahul Mahida; Alice M Turner; Elizabeth Sapey; Wenbin Wei; Babu Naidu; Paul M Stewart; William D Fraser; Kenneth B Christopher; Mark S Cooper; Fang Gao; David M Sansom; Adrian R Martineau; Gavin D Perkins; David R Thickett Journal: Thorax Date: 2015-04-22 Impact factor: 9.139
Authors: Karin Amrein; Christian Schnedl; Andrea Berghold; Thomas R Pieber; Harald Dobnig Journal: BMC Endocr Disord Date: 2012-11-07 Impact factor: 2.763
Authors: Karin Amrein; Paul Zajic; Christian Schnedl; Andreas Waltensdorfer; Sonja Fruhwald; Alexander Holl; Tadeja Purkart; Gerit Wünsch; Thomas Valentin; Andrea Grisold; Tatjana Stojakovic; Steven Amrein; Thomas R Pieber; Harald Dobnig Journal: Crit Care Date: 2014-03-24 Impact factor: 9.097
Authors: Elizabeth M Viglianti; Sean M Bagshaw; Rinaldo Bellomo; Joanne McPeake; Xiao Qing Wang; Sarah Seelye; Theodore J Iwashyna Journal: Intensive Care Med Date: 2020-06-04 Impact factor: 17.440
Authors: Elizabeth M Viglianti; Erin F Carlton; Joanne McPeake; Xiao Qing Wang; Sarah Seelye; Theodore J Iwashyna Journal: Medicine (Baltimore) Date: 2022-07-08 Impact factor: 1.817
Authors: Martin Shaw; Elizabeth M Viglianti; Joanne McPeake; Sean M Bagshaw; David Pilcher; Rinaldo Bellomo; Theodore J Iwashyna; Tara Quasim Journal: Crit Care Explor Date: 2020-04-29
Authors: Theodore S Jennaro; Elizabeth M Viglianti; Nicholas E Ingraham; Alan E Jones; Kathleen A Stringer; Michael A Puskarich Journal: J Clin Med Date: 2022-01-26 Impact factor: 4.241